Premium
A putative PPAR beta/delta agonist induces cell death in human cancer cell lines
Author(s) -
Strom David Kelly,
Li Dalon,
Brinkman Hanna,
Gleason Stephanie,
Hershberger Sarah,
Cumbay Medhane,
LaFontaine Michael,
Boncher Tracey,
Hegwood Emma
Publication year - 2018
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.2018.32.1_supplement.836.9
Subject(s) - apoptosis , agonist , receptor , cell culture , beta (programming language) , peroxisome proliferator activated receptor , cancer research , ppar agonist , biology , chemistry , microbiology and biotechnology , pharmacology , biochemistry , genetics , computer science , programming language
Compound 9 was specifically developed as an agonist for PPAR beta/delta. Binding studies showed it also bound PPAR gamma. Because of the recent identification of PPAR beta/delta involvement in a number of cancers, we tested whether compound 9 would synergize with known chemotherapeutic agents to increase apoptosis in a human cancer cell line that expresses the PPAR beta/delta receptor. These studies revealed that compound 9 was capable of inducing apoptosis on its own, and did not synergize with doxorubicin in inducing apoptosis. We have undertaken a series of studies to determine if the apoptosis that compound 9 induces is being mediated through any of the PPAR receptors. We have also examined compound 9 ability to signal through the PPAR receptors in a variety of cell lines. This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom